Universidade Federal de Pernambuco, Postgraduate Program in Therapeutic Innovation - Recife (PE), Brazil.
State Health Secretariat of Pernambuco, Correia Picanço Hospital - Recife (PE), Brazil.
Rev Assoc Med Bras (1992). 2021 Mar;67(3):449-453. doi: 10.1590/1806-9282.20200765.
Triggering receptor expressed on myeloid cells-1 concentration can be used as a predictive, diagnostic, and prognostic marker in patients with sepsis. The objective of this study was to determine the validity of triggering receptor expressed on myeloid cells-1 levels as a biomarker of sepsis in pediatric patients.
This was an integrative literature review. PubMed, ScienceDirect, LILACS, MEDLINE, and VHL databases were searched for papers published between 2015 and 2020, using the keywords triggering receptor expressed on myeloid cells-1, sepsis, and child.
The review included ten studies, of which four used triggering receptor expressed on myeloid cells-1 as a predictive biomarker; four, as a diagnostic biomarker; and two, as a prognostic biomarker. A total of 1,409 and 1,628 patients were included in primary and review studies, respectively. There was a predominance of significant results for the validity of triggering receptor expressed on myeloid cells-1 levels in the prediction, diagnosis, and prognosis of sepsis in pediatric patients.
Triggering receptor expressed on myeloid cells-1 is a valid predictive, diagnostic, and prognostic biomarker of sepsis with good sensitivity and specificity in the pediatric population.
髓样细胞触发受体-1 浓度可作为脓毒症患者的预测、诊断和预后标志物。本研究旨在确定髓样细胞触发受体-1 水平作为儿科脓毒症患者生物标志物的有效性。
这是一项综合文献回顾。使用髓样细胞触发受体-1、脓毒症和儿童等关键词,在 PubMed、ScienceDirect、LILACS、MEDLINE 和 VHL 数据库中搜索了 2015 年至 2020 年期间发表的论文。
综述纳入了 10 项研究,其中 4 项研究将髓样细胞触发受体-1 用作预测生物标志物,4 项研究用作诊断生物标志物,2 项研究用作预后生物标志物。在纳入的原始研究和综述研究中,分别有 1409 例和 1628 例患者。髓样细胞触发受体-1 水平在儿科脓毒症患者的预测、诊断和预后中的有效性具有显著结果的优势。
髓样细胞触发受体-1 是一种有效的预测、诊断和预后生物标志物,在儿科人群中具有良好的敏感性和特异性。